RxDoctor Payments Data

Benedict Ciszek, MD

Family Medicine · Chicago, ILNPI 1881898617

Payments from drug & device makers

$2,234in general payments, 2019–2025

Across 75 payments — averaging $29.78 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Abbott$331
  • Corcept Therapeutics$321
  • Novo Nordisk$246
  • Spinal Simplicity, LLC$181
  • Lundbeck LLC$159
  • Pfizer$146
  • plus $849 from 23 others

What the payments were for

  • Speaking & faculty fees$151%
  • Food & beverage$2,21999%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,234 in reported general payments places this provider in the 80th percentile of 4,116 family medicine providers in Illinois.

See all family medicine providers in Illinois

Medicare billing

Part B allowed, 2024
$37,478
Medicare patients
159
Services billed
439

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide34$61,455
BiktarvyBictegrav/Emtricit/Tenofov Ala12$55,415
EliquisApixaban44$54,919
XareltoRivaroxaban15$17,179
Breo ElliptaFluticasone/Vilanterol17$6,621
Atorvastatin Calcium330$3,207
Metoprolol Succinate151$2,374
Advair DiskusFluticasone Propion/Salmeterol11$2,221
Lisinopril245$2,088
Levothyroxine Sodium160$1,984
Amlodipine Besylate205$1,723
SynthroidLevothyroxine Sodium14$1,425
Gabapentin57$1,419
Losartan Potassium160$1,416
Albuterol Sulfate HfaAlbuterol Sulfate45$1,283

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$246$61,45534 claims
PfizerEliquis$146$54,91944 claims
GSKBreo Ellipta$33$6,62117 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 4,116 family medicine providers in Illinois.

Other family medicine in Chicago

See the full list for Illinois

Where these figures come from

Is this you, or does something look wrong? →